Filovirus Animal Models; Public Workshop, 42099 [E7-14874]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
allocated in accordance with section
2604 of the Act and must be treated by
LIHEAP grantees receiving them as an
amount appropriated for FY 2007. As
FY 2007 funds, they will be subject to
all requirements of the Act, including
section 2607(b)(2), which requires that a
grantee obligate at least 90 percent of its
total block grant allocation for a fiscal
year by the end of the fiscal year for
which the funds are appropriated, that
is, by September 30, 2007.
FOR FURTHER INFORMATION CONTACT: Nick
St. Angelo, Director, Division of Energy
Assistance, Office of Community
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447; telephone (202)
401–9351.
Dated: July 26, 2007.
Yolanda J. Butler,
Deputy Director, Office of Community
Services.
[FR Doc. E7–14875 Filed 7–31–07; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Filovirus Animal Models; Public
Workshop
AGENCY:
National Institutes of Health,
HHS.
jlentini on PROD1PC65 with NOTICES
ACTION:
Notice of public workshop.
The National Institutes of Health
(NIH) is announcing a public workshop
entitled: Filoviruses: Current Status of
Research into Pathophysiology and
Potential Uses of Animal Models. The
purpose of the public workshop is to
discuss the current state of
understanding of filovirus infections,
knowledge gaps and research needs, the
current status of research exploring
animal models, and the potential role of
model development in approaches to
investigation of therapeutic or vaccine
strategies directed towards filoviruses.
DATE AND TIME: The public workshop
will be held on September 11, 2007
from 8:30 a.m.–5 p.m. and on September
12, 2007 from 8:30 a.m.–1 p.m.
LOCATION: The public workshop will be
held at the main auditorium, Natcher
Conference Center, NIH Campus, 45
Center Drive, Bethesda, Maryland.
CONTACT PERSON: Ping Chen, 6610
Rockledge Drive, telephone: 301–451–
3756, fax: 301–480–1263, e-mail:
chenpi@niaid.nih.gov
REGISTRATION: Pre-registration is
required and must be completed by
August 24, 2007. Please go to the
following web site for information about
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
registration (https://www.niaid.nih.gov/
news/events/meetings/filo/). There is no
registration fee for the public workshop.
Early registration is recommended
because seating is limited. There will be
no onsite registration.
If you need special accommodations
due to a disability, please contact (see
Contact Person) at least 7 days in
advance.
SUPPLEMENTARY INFORMATION: NIH, CDC,
DoD, and FDA, are cosponsoring a
public workshop titled, ‘‘Filoviruses:
Current Status of Research into
Pathophysiology and Potential Uses of
Animal Models’’. The meeting will
discuss: (1) Background information on
filovirus pathogenesis and clinical
disease in humans and animals, and
status of research into the
understanding of human disease and
development of animal models; (2)
Background information on the
scientific issues and regulatory
approaches to the potential uses of
animal data in the development of
prevention and treatment strategies; (3)
General review of filovirus vaccine
design, rationale, and correlates of
protection; (4) General review of the
status of preliminary research
approaches to filovirus-directed
antiviral therapeutics. The workshop’s
goal is to enhance understanding of
filovirus disease, identify knowledge
gaps and research needs, and explore
the potential strengths and limitations
of various animal models.
TRANSCRIPTS: Transcripts of the public
workshop will be available following
the workshop. Procedures to obtain a
transcript will be made available at a
later date.
Dated: July 23, 2007.
Michael G. Kurilla,
Director, Office of Biodefense Research
Affairs, Associate Director for Biodefense
Product Development, DMID, NIAID, National
Institutes of Health.
[FR Doc. E7–14874 Filed 7–31–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Delegation of Authority
Notice is hereby given that I have
delegated to the Director, National
Institutes of Health (NIH), the
authorities under section 3 of Public
Law 109–416 (Combating Autism Act of
2006), which amends Title III of the
Public Health Service Act, by adding
Part R, section 399CC, authorizing
establishment of the Interagency Autism
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
42099
Coordinating Committee. I am also
delegating the authority under Title III,
section 399CC of the Public Health
Service Act, as amended, to select
Federal members of the Committee,
including the chair, as appropriate. I
will retain the authority under Title III,
section 399CC(c)(2), pertaining to the
selection of additional non-Federal
public members of the Committee.
This delegation excludes the authority
to submit reports to the Congress, and
shall be exercised in accordance with
the Department’s applicable policies,
procedures, and guidelines relating to
regulations.
This delegation is effective upon
signature. In addition, I ratified and
affirmed any actions taken by the
Director of the NIH or his subordinates
which involved the exercise of the
authorities delegated herein prior to the
effective date of the delegation.
This delegation was effective upon
date of signature.
Dated: July 18, 2007.
Michael O. Leavitt,
Secretary.
[FR Doc. 07–3735 Filed 7–31–07; 8:45 am]
BILLING CODE 4160–18–M
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5155–N–01]
Mortgage and Loan Insurance
Programs Under the National Housing
Act—Debenture Interest Rates
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Notice.
AGENCY:
SUMMARY: This notice announces
changes in the interest rates to be paid
on debentures issued with respect to a
loan or mortgage insured by the Federal
Housing Administration under the
provisions of the National Housing Act
(the Act). The interest rate for
debentures issued under section
221(g)(4) of the Act during the 6-month
period beginning July 1, 2007, is 43⁄4
percent. The interest rate for debentures
issued under any other provision of the
Act is the rate in effect on the date that
the commitment to insure the loan or
mortgage was issued, or the date that the
loan or mortgage was endorsed (or
initially endorsed if there are two or
more endorsements) for insurance,
whichever rate is higher. The interest
rate for debentures issued under these
other provisions with respect to a loan
or mortgage committed or endorsed
during the 6-month period beginning
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 72, Number 147 (Wednesday, August 1, 2007)]
[Notices]
[Page 42099]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-14874]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Filovirus Animal Models; Public Workshop
AGENCY: National Institutes of Health, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
The National Institutes of Health (NIH) is announcing a public
workshop entitled: Filoviruses: Current Status of Research into
Pathophysiology and Potential Uses of Animal Models. The purpose of the
public workshop is to discuss the current state of understanding of
filovirus infections, knowledge gaps and research needs, the current
status of research exploring animal models, and the potential role of
model development in approaches to investigation of therapeutic or
vaccine strategies directed towards filoviruses.
Date and Time: The public workshop will be held on September 11, 2007
from 8:30 a.m.-5 p.m. and on September 12, 2007 from 8:30 a.m.-1 p.m.
Location: The public workshop will be held at the main auditorium,
Natcher Conference Center, NIH Campus, 45 Center Drive, Bethesda,
Maryland.
Contact Person: Ping Chen, 6610 Rockledge Drive, telephone: 301-451-
3756, fax: 301-480-1263, e-mail: chenpi@niaid.nih.gov
Registration: Pre-registration is required and must be completed by
August 24, 2007. Please go to the following web site for information
about registration (https://www.niaid.nih.gov/news/events/meetings/filo/
). There is no registration fee for the public workshop. Early
registration is recommended because seating is limited. There will be
no onsite registration.
If you need special accommodations due to a disability, please
contact (see Contact Person) at least 7 days in advance.
SUPPLEMENTARY INFORMATION: NIH, CDC, DoD, and FDA, are cosponsoring a
public workshop titled, ``Filoviruses: Current Status of Research into
Pathophysiology and Potential Uses of Animal Models''. The meeting will
discuss: (1) Background information on filovirus pathogenesis and
clinical disease in humans and animals, and status of research into the
understanding of human disease and development of animal models; (2)
Background information on the scientific issues and regulatory
approaches to the potential uses of animal data in the development of
prevention and treatment strategies; (3) General review of filovirus
vaccine design, rationale, and correlates of protection; (4) General
review of the status of preliminary research approaches to filovirus-
directed antiviral therapeutics. The workshop's goal is to enhance
understanding of filovirus disease, identify knowledge gaps and
research needs, and explore the potential strengths and limitations of
various animal models.
Transcripts: Transcripts of the public workshop will be available
following the workshop. Procedures to obtain a transcript will be made
available at a later date.
Dated: July 23, 2007.
Michael G. Kurilla,
Director, Office of Biodefense Research Affairs, Associate Director for
Biodefense Product Development, DMID, NIAID, National Institutes of
Health.
[FR Doc. E7-14874 Filed 7-31-07; 8:45 am]
BILLING CODE 4140-01-P
